Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (61-70 of 255) with videos related to

Pageof 26
Sort By:
Clinical Genitourinary Cancer|June 25, 2016
Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate CancerScott J Parker, Gregory R Pond, Neeraj Agarwal, et al.
Gynecologic Oncology|October 3, 2022
Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort studyLimor Helpman, Gregory R Pond, Laurie Elit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Randomized phase II trials: inevitable or inadvisable?Hui K Gan, Axel Grothey, Gregory R Pond, et al.
Cancer|December 6, 2002
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinomaBrigette B Y Ma, Ian F Tannock, Gregory R Pond, et al.
Journal of Cancer Survivorship : Research and Practice|October 14, 2022
A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairmentJanette L Vardy, Gregory R Pond, Melanie L Bell, et al.
Journal of Thoracic Disease|March 13, 2023
Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancerMohammad Gouran-Savadkoohi, Aruz Mesci, Gregory R Pond, et al.
BJU International|April 24, 2012
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapyGregory R Pond, Andrew J Armstrong, Brian A Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patternsCarol A Townsley, Kendra Naidoo, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyDominik R Berthold, Gregory R Pond, Freidele Soban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trialStephen Chia, Mark Clemons, Lee-Ann Martin, et al.
Pageof 26

Showing results (61-70 of 255) with videos related to

Sort By:
Pageof 26
Clinical Genitourinary Cancer|June 25, 2016
Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate CancerScott J Parker, Gregory R Pond, Neeraj Agarwal, et al.
Gynecologic Oncology|October 3, 2022
Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort studyLimor Helpman, Gregory R Pond, Laurie Elit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Randomized phase II trials: inevitable or inadvisable?Hui K Gan, Axel Grothey, Gregory R Pond, et al.
Cancer|December 6, 2002
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinomaBrigette B Y Ma, Ian F Tannock, Gregory R Pond, et al.
Journal of Cancer Survivorship : Research and Practice|October 14, 2022
A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairmentJanette L Vardy, Gregory R Pond, Melanie L Bell, et al.
Journal of Thoracic Disease|March 13, 2023
Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancerMohammad Gouran-Savadkoohi, Aruz Mesci, Gregory R Pond, et al.
BJU International|April 24, 2012
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapyGregory R Pond, Andrew J Armstrong, Brian A Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patternsCarol A Townsley, Kendra Naidoo, Gregory R Pond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyDominik R Berthold, Gregory R Pond, Freidele Soban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trialStephen Chia, Mark Clemons, Lee-Ann Martin, et al.
Pageof 26